Month

June 2015
OTTAWA – Health Canada initiated a safety review for the prescription diabetes drugs dapagliflozin (Forxiga) and canagliflozin (Invokana) and the risk of ketoacidosis, a serious condition that leads to high levels of blood acids called ketones. Dapagliflozin and canagliflozin are known as SGLT2 (sodium-glucose cotransporter-2) inhibitors and are approved in Canada for use in patients […]
Read More
On May 15, 2015 the FDA announced it is investigating an association between Farxiga, Jardiance, and Invokana with diabetic ketoacidosis (DKA), ketoacidosis, or ketosis.  See: “FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood”. About a month later, Health Canada […]
Read More
COVID-19 UPDATE: Your health and safety are of the utmost importance to us. But we also know that your legal issues can’t wait.Learn More >>